D.E. Shaw & Co
TBRA

D.E. Shaw & Co’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

D.E. Shaw & Co’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,248
Closed -$25K – 3998
2015
Q1 		$25K Buy
+2,248
New +$24.1K ﹤0.01% 3568

Other funds holding TBRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's TBRA Position: Q2 2015 in Review

D.E. Shaw & Co sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2015, closing a stake of 2,248 shares — an estimated $25K sold.

D.E. Shaw & Co first reported a position in TBRA in Q1 2015 and held it in 1 quarter. The position peaked at $25K in Q1 2015. 42 funds tracked by Wall St. Rank hold TBRA as of Q2 2015.

  • D.E. Shaw & Co reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,248 Tobira Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $25K.
  • D.E. Shaw & Co first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • D.E. Shaw & Co's Tobira Therapeutics, Inc. Common Stock position peaked at $25K in Q1 2015.
  • 42 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2015.

Based on D.E. Shaw & Co's 13F filing for Q2 2015, filed 14 Aug 2015.